Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission
HIV Infections, AIDS, Sexually Transmitted Diseases
About this trial
This is an interventional prevention trial for HIV Infections focused on measuring Microbicide, HIV, AIDS, STIs, STDs, Efficacy, HSV, Women, South Africa, seroconversion, condom, safe-sex, vaginal intercourse, prevention, HIV Seronegativity
Eligibility Criteria
Inclusion Criteria: HIV negative and agree to be tested for HIV and told their results at all visits during the study Aged 16 - 40 years of age Have had at least one vaginal intercourse within the last three months Willing and able to give written informed consent (or if desired, consent provided by parent or guardian with written assent from the minor participant) Provide locator information to study staff throughout the trial Comply with all aspects of the study protocol, including random assignment to the Carraguard® plus condom or placebo plus condom arm, clinical valuations, specimen collection and testing, visit schedule and study drug regimen Citizen or permanent resident of South Africa Resident for the past year and intends to reside in the catchment area of the site for the next two years During the study, will not use any vaginal products except tampons or those prescribed or approved by the study clinician. Exclusion Criteria: Currently pregnant, or indicate a desire to become pregnant in the next two years at the time of screening Within four weeks of last pregnancy outcome at the time of enrolment Pap smear at screening is graded as carcinoma. Injected illicit drugs in the 12 months prior to screening Participating in any other clinical trial/HIV prevention study
Sites / Locations
- Isipingo Clinic
- Empilisweni Clinic
- Setshaba Research Clinic, University of Limpopo - Medunsa Campus